Introduction: In degenerative mitral regurgitation (MR), brain natriuretic peptide (BNP) is a surrogate biomarker of the consequences of MR on the left ventricle (LV) and left atrium (LA). LV global longitudinal strain (GLS), quantified by 2-D speckle-tracking imaging (2DSt) improved the detection of subclinical LV dysfunction. We aimed at evaluating the impact of BNP on outcome and its relationship with GLS, in asymptomatic patients with degenerative MR. Methods and results: Comprehensive transthoracic echocardiography including 2DSt quantification was performed in 135 consecutive asymptomatic patients (60+14 years, 55% of male) with moderate to severe degenerative MR (61% with severe MR) and preserved LV function. Simultaneously, blood sample was drawn and plasma BNP level was measured. BNP widely varied over patients (mean=61+70, range: 5-439, median= 41pg/ml) and was correlated with age (r=0.28, p=0.009), indexed LV endsystolic diameter (r=0.30, p=0.0006), indexed LA volume (r=0.51, p,0.0001), E/Ea ratio (r=0.33, p,0.0001), systolic pulmonary pressure (r=0.24, p=0.006) and GLS (r=-0.54, p,0.0001). On multiple regression analysis, only indexed LA volume and GLS were independently associated with BNP (b=1.1+0.4, p=0.002 and b=-6.6+1.4, p,0.001, respectively). During follow-up (mean=23+19 months), 54 events occurred resulting in a 4-year cardiac event-free survival=50+6%. According to the median of BNP, patients with high BNP level had significant reduced eventfree survival (21+8% vs. 75+6%, p,0.0001). A GLS,23% was also associated with a lower event-free survival (85+6% vs. 33+7%, p,0.0001). In Cox multivariate analysis, after adjustment for age, sex, E/Ea ratio and indexed end-systolic diameter, only indexed LA volume (hazard ratio [HR]=1.01, 95% confidence interval [CI]: 1.0-1.3, p=0.036), GLS,23% (HR=3.3, 95%CI: 1.1-9.9, p=0.03) and BNP,41pg/ml (HR=3.5, 95%CI: 1.7-7.2, p=0.001) were independent determinants of cardiac eventfree survival. In addition, compared to the first quartile of BNP (,19pg/ml), second (19-41pg/ml), third (42-70pg/ml) and fourth (71-439pg/ml) quartiles of BNP were associated with a 3.5-, 10-and 11-fold increase in risk of cardiac events (p=0.06, p,0.0001 and p,0.0001, respectively). Conclusion: In asymptomatic degenerative MR, LV longitudinal function and LA volume are the main determinants of BNP release. BNP is a powerful independent predictor of cardiac events. Assessment of plasma BNP level, LA volume, and LV longitudinal function may help to improve risk stratification and the management of these patients.
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Prevalence and characteristics of paradoxical low Flow, low gradient severe aortic stenosis: results from a cardiac catheterization study. Background: About 15-20% of patients with severe aortic stenosis (AS) (aortic valve area, AVA ≤ 1 cm 2 ) have a low transvalvular flow and a low mean gradient despite preserved left ventricular ejection fraction (LVEF). This entity, named paradoxical low flow, low gradient (PLFLG) AS, was initially described using Doppler-echocardiography. However, some concerns were raised about potential overestimation of its prevalence by echo. Aim was to describe the prevalence and characteristics of patients with PLFLG AS using cardiac catheterization. Methods and Results: Between 1994 and 2010, 2005 patients underwent cardiac catheterization for evaluation of AS severity and identification of coronary artery disease prior to aortic valve replacement (AVR). Of these, we excluded those with other valvular heart disease or with LVEF , 50%. Of the remaining 1296 pts, 58% of patients had an AVA≤ 1 cm 2 and a mean gradient .40mm Hg (classical severe AS), whereas 23% had an AVA≤ 1 cm 2 but a mean gradient ,40mm Hg; In comparison to patients with Classical severe AS (table), those with PLFLG AS were significantly older, more often female, had lower cardiac output, higher systolic blood pressure, and pulmonary vascular resistance. The % of patients who finally underwent AVR was lower (85 vs. 95%) and that of patients who had concomitant CABG was higher (38 vs. 31%) in patients with PLFLG AS. Conclusion: This study shows PLFLG severe AS is a frequent entity with up to 23% of patients with severe AS referred to AVR. These patients had more frequent co-morbidities.These findings further underlines the importance to correctly identify this entity so we do not deny surgery to patients with a small AVA and a low gradient despite preserved LVEF. Background: We sought to assess the impact of a valve clinic based regular follow-up program on timing of surgery for patients with severe aortic stenosis (AS). Methods: The severity of symptom onset and the delay in symptom reporting was assessed in 388 consecutive patients (198 female, age 71+10 yrs) having an indication for aortic valve replacement due to AS based on current practice guidelines. Of these, 100 patients had been regularly followed in our valve clinic (including serial clinical and echocardiographic exams): these patients were instructed to promptly report the onset of symptoms and had developed indications for surgery during follow-up. 288 pts presented with an indication for surgery at first presentation in our valve clinic. Results: AS severity (peak aortic-jet velocity 5.1+0.6 m/s, aortic valve area 0.6+0.2 cm2) and prevalence of cardiovascular risk factors (hypertension, hypercholesterinemia, diabetes or coronary artery disease) were not significantly different between the two groups. The delay of symptom reporting was significantly longer in the group of patients being symptomatic at the first visit (351+471 days) than for patients being Eur J Echocardiography Abstracts Supplement, December 2011 doi:10.1093/ejechocard/jer200 regularly followed (88+141 days, p,0.001). Despite being instructed to promptly report symptoms after their onset, only 21 of the 100 patients being regularly followed reported a symptom-onset before their next scheduled exam (delay of symptom onset reporting: 21+26 days), whereas 79 of these 100 patients reported symptoms at the scheduled follow-up visit only (delay of symptom onset reporting: 106+154 days, p,0.001). Severe symptom onset (NYHA or CCS class ≥ 2.5) was observed in 61% of patients being symptomatic at their first visit and in 33% ofpatients followed in the valve clinic (p,0.001). A very severe symptom onset (NYHA or CCS ≥ 3) was found in 25% of patients who presented with an indication for surgery and in 9% of patients enrolled in the follow-up program (p,0.001).
Conclusion: Delayed symptom reporting is common in patients with aortic stenosis. In patients being regularly followed in a valve clinic program, symptoms are detected at an earlier and less severe stage resulting in optimized timing of aortic valve surgery. These findings also emphasise on the importance of risk stratification to identify patients benefiting from elective surgery. Results: The groups did not differ in age, gender. LV end diastolic and systolic diameters and volumes were higher in AR groups (p,0.001). LV ejection fraction was slightly reduced in symptomatic AR compared with asymptomatic AR and controls (52,0+8,87% vs 57,9+4,91% vs 59,3+3,64%; p≤0.001). The ratio E/E' was higher in symptomatic AR compared with asymptomatic AR and controls (10,3+4,1 vs 7,8+2,4 vs 10,3+4,1 respectively; p,0.001). The global systolic SL was lower in symptomatic and asymptomatic AR groups compared to the controls (216.3+3.8% vs 218.8+2,4% vs 220.3+2.1 % respectively, p,0.01), and the SL in symptomatic AR was lower compared to asymptomatic AR (p,0,01). Asymptomatic AR had increased apical rotation (11.6+4.50 vs 9.6+4.20, p,0.05) and twist (18.1+5.70 vs 16.3+4.90, p,0.05) compared to controls. LV torsion (1.7+0.58 vs 2.05+0.72, p,0.05), SR (37.0+11.1 vs 45.8+11.8, p,0.05) and SC (219.3+3.6 vs 221.1+2.8, p,0.05) were reduced in symptomatic AR compared to asymptomatic AR. Multiple regression logistic analysis (age, SL, SR, SC, LV end systolic diameter, torsion were included into analysis) showed global SL (OR 1.28, 95% CI 1.0-1.62, p¼0.04) and E/E' ratio (OR 1.3, 95% CI 1.06-1.58, p¼0.009) as independent predictors for heart failure symptoms. ROC analysis revealed that a global SL of -17.8 % was best predictor of symptoms with 77% sensitivity and 68% specificity (AUC 0.73, p,0.001, 95% CI 0.61-0.84).
Conclusions: Asymptomatic AR is related with reduced LV SL, increased apical rotation and twist, whereas symptomatic AR have reduced LV torsion, SC and SR. Reduced global SL predicts heart failure symptoms.
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